Hostname: page-component-745bb68f8f-b95js Total loading time: 0 Render date: 2025-01-09T04:14:04.676Z Has data issue: false hasContentIssue false
  • English
  • Français

The use of antithrombotic drugs for primary and secondary prevention of ischaemic stroke

Published online by Cambridge University Press:  17 November 2008

Richard J Davenport  and
Martin S Dennis
Richard J Davenport*
Affiliation:
University of Edinburgh, Edinburgh, UK
Martin S Dennis
Affiliation:
University of Edinburgh, Edinburgh, UK
*
Richard J Davenport, University of Edinburgh, Department of Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK.
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Clinical geriatrics
Information
Reviews in Clinical Gerontology , Volume 6 , Issue 4 , November 1996 , pp. 315 - 323
Copyright
Copyright © Cambridge University Press 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Harris, AI. Handicapped and impaired in Great Britain. London: HMSO, 1971.Google Scholar
2Bamford, J, Sandercock, P, Dennis, M, Burn, J, Warlow, C. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981–86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 1990; 53: 16–22.CrossRefGoogle Scholar
3Dennis, M, Bamford, J, Sandercock, P, Warlow, C. Prognosis of transient ischemic attacks in the Oxfordshire Community Stroke Project. Stroke 1990; 21: 848–53.CrossRefGoogle ScholarPubMed
4Hankey, GJ, Warlow, CP. Transient ischaemic attacks of the brain and eye. London: WB Saunders, 1994.Google Scholar
5Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy 1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106.CrossRefGoogle Scholar
6Slattery, J, Warlow, CP, Shorrock, CJ, Langman, MJS. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin-analysis of gastrointestinal bleeding during the UK-TIA trial. Gut 1995; 37: 509–11.CrossRefGoogle ScholarPubMed
7Warlow, C. Ticlopidine, a new antithrombotic drug: but is it better than aspirin for longterm use? J Neurol Neurosurg Psychiatry 1990; 53: 185–87.CrossRefGoogle ScholarPubMed
8 Anon. Major ongoing stroke trials. Stroke 1995; 26: 1978–82.Google Scholar
9Meade, TW, Wilkes, HC, Stirling, Y, Brennan, PJ, Kelleher, C, Browne, W. Randomized controlled trial of low dose warfarin in the primary prevention of ischaemic heart disease in men at high risk: design and pilot study. Eur Heart J 1988; 9: 836–43.CrossRefGoogle ScholarPubMed
10Jonas, S. Anticoagulant therapy in cerebrovascular disease: review and meta-analysis. Stroke 1988; 19: 1043–48.CrossRefGoogle ScholarPubMed
11ASPECT Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 343: 499–503.Google Scholar
12Smith, P, Arnesen, H, Holme, I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147–52.CrossRefGoogle ScholarPubMed
13Cairns, JA. Oral anticoagulants or aspirin after myocardial infarction? Lancet 1994; 343: 497–98.CrossRefGoogle ScholarPubMed
14Bogousslavsky, J, Hachinski, VC, Boughner, DR, Fox, AJ, Viñuela, F, Barnett, HJM. Cardiac and arterial lesions in carotid transient ischemie attacks. Arch Neurol 1986; 43: 223–28.CrossRefGoogle Scholar
15Sandercock, PA, Warlow, CP, Jones, LN, Starkey, IR. Predisposing factors for cerebral infarction: the Oxfordshire community stroke project. BMJ 1989; 298: 75–80.CrossRefGoogle ScholarPubMed
16Wolf, PA, Dawber, TR, Thomas, HE, Kannel, WB. Epidemiological assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28: 973–77.CrossRefGoogle ScholarPubMed
17Flegel, KM, Shipley, MJ, Rose, G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet 1987; i: 526–29.CrossRefGoogle Scholar
18Rose, G, Baxter, PJ, Reid, DD, McCartney, P. Prevalence and prognosis of electrocardiographic findings in middle-aged men. Br Heart J 1978; 40: 636–43.CrossRefGoogle ScholarPubMed
19Kannel, WB, Abbott, RD, Savage, DD, McNamara, PM. Epidemiological features of chronic atrial fibrillation. N Engl J Med 1982; 306: 1018–22.CrossRefGoogle ScholarPubMed
20Ostrander, LD, Brandt, RL, Kjelsberg, MO, Epstein, FH. Electrocardiography findings among the adult population of a total natural community, Tecumseh, Michigan. Circulation 1965; 31: 888–98.CrossRefGoogle ScholarPubMed
21Petersen, P, Boysen, G, Godtfredsen, J, Andersen, ED, Andersen, B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175–79.CrossRefGoogle ScholarPubMed
22The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505–11.CrossRefGoogle Scholar
23Connolly, SJ, Laupacis, A, Gent, M, Roberts, RS, Cairns, JA, Joyner, C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349–55.CrossRefGoogle ScholarPubMed
24Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84: 527–39.CrossRefGoogle Scholar
25Ezekowitz, MD, Bridgers, SL, James, KE et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327: 1406–12.CrossRefGoogle ScholarPubMed
26Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687–91.Google Scholar
27Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154: 1449–57.CrossRefGoogle Scholar
28Gustafsson, C, Asplund, K, Britton, M, Norrving, B, Olsson, B, Marké, L. Cost-effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ 1992; 305: 1457–60.CrossRefGoogle ScholarPubMed
29Sweeney, KG, Pereira, Gray DJ, Steele, RJF, Evans, PH. Commentary: caution needed in introducing warfarin treatment. BMJ 1995; 311: 560–61.CrossRefGoogle ScholarPubMed
30Sudlow, CM, Rodgers, H, Kenny, RA, Thomson, RG. Service provision and use of anticoagulants in atrial fibrillation. BMJ 1995; 311: 558–60.CrossRefGoogle ScholarPubMed
31EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255–62.CrossRefGoogle Scholar
32Koudstaal, P. Secondary prevention following stroke or transient ischaemic attack in patients with nonrheumatic atrial fibrillation: antiplatelet therapy versus control. In: Warlow, C, Van Gijn, J, Sandercock, P eds. Stroke module of the Cochrane database of systematic reviews. London: BMJ Publishing Group, 1995.Google Scholar
33Koudstaal, P. Secondary prevention following stroke or transient ischaemic attack in patients with nonrheumatic atrial fibrillation: anticoagulant therapy versus control. In: Warlow, C, Van Gijn, J, Sandercock, P eds. Stroke module of the Cochrane database of systematic reviews. London: BMJ Publishing Group, 1995.Google Scholar
34Koudstaal, P. Secondary prevention following stroke or transient ischaemic attack in patients with nonrheumatic atrial fibrillation: anticoagulant versus antiplatelet therapy. In: Warlow, C, Van Gijn, J, Sandercock, P eds. Stroke module of the Cochrane database of systematic reviews. London: BMJ Publishing Group, 1995.Google Scholar
35Sandercock, P, Bamford, J, Dennis, M et al. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project). BMJ 1992; 305: 1460–65.CrossRefGoogle ScholarPubMed
36The UK-TIA Study Group. Intracranial tumours that mimic transient cerebral ischaemia: lessons from a large multicentre trial. J Neurol Neurosurg Psychiatry 1993; 56: 563–66.CrossRefGoogle Scholar
37Rimdusid, P, Wardlaw, J, Lindley, RI, Sandercock, P. Haemorrhagic infarction in acute ischaemic stroke patients: International Stroke Trial Pilot Study [Abstract]. Cerebrovasc Dis 1995; 5: 264.Google Scholar
38International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (1ST), baseline data, and outcome in 984 randomised patients in the pilot study. J Neurol Neurosurg Psychiatry 1996; 60: 371–76.CrossRefGoogle Scholar